Enzo Biochem says ransomware attack exposed clinical test data of 2.5 million patients

Enzo Biochem, a New York-based biotechnology company, has confirmed that a ransomware attack exposed the clinical test information of almost 2.5 million patients.

Enzo, which manufactures and sells DNA-based tests to detect viral and bacterial diseases, including COVID-19 and cancer, confirmed in an SEC filing this week that it experienced a ransomware attack on April 6.